Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model t
about
Definition of a molecular pathway mediating α-synuclein neurotoxicityEvaluation of Models of Parkinson's DiseaseCharacterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectorsChronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell lossTowards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in MacaqueIntrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degenerationProgressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.Relative contributions of severe dopaminergic neuron ablation and dopamine depletion to cognitive impairment.α-Synuclein and nonhuman primate models of Parkinson's diseaseEndoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo.Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases.Direct detection of alpha synuclein oligomers in vivoAAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.Pathways towards an effective immunotherapy for Parkinson's diseaseInflammation and adaptive immunity in Parkinson's disease.Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.α-Synuclein nonhuman primate models of Parkinson's disease.Animal models of α-synucleinopathy for Parkinson disease drug development.Spinal cord stimulation improves forelimb use in an alpha-synuclein animal model of Parkinson's disease.Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.In vivo models of alpha-synuclein transmission and propagation.Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression.FKBP12 contributes to α-synuclein toxicity by regulating the calcineurin-dependent phosphoproteome.MicroRNAs in Parkinson's disease and emerging therapeutic targets.A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.
P2860
Q26269832-8E0840C3-FA9C-484B-BFC9-83ADA43242E5Q26772843-C920C6F2-C4B2-4041-A557-E3C154E4DFCEQ27318127-471A6C4F-8A48-4F56-9258-F8C62962868DQ28538890-96AF4176-2906-477D-B44C-9697B12C3FFDQ28554611-EF13C090-0A39-4498-B512-95B917574CCDQ30373366-3FDC230B-8510-4173-A165-B14F1073A495Q33847712-FEEA01A4-19DD-4729-AFDD-5FF3CB769035Q34465572-2C20E34A-5E71-4987-A228-FA4FBE22CBFDQ35853990-FBB1B852-C617-47DC-98D5-45B16967A56EQ36101699-92B3C307-C486-45A7-A226-66328849EC81Q36157306-506B0C41-C10E-47A2-9BB3-7B9D44F12A6EQ36289970-87B0A0E4-A311-4815-A6BB-D055CD305793Q36460964-9BC99ADA-2797-41DB-A1AE-DDD9FB6A5F84Q37180232-9B8E38AB-6B12-4741-A2A1-1889CDCC2857Q37618665-1D9349C3-1E43-4D7B-9923-1B35DB853C9BQ37957125-B9D29D1B-307B-4541-861D-FD1CF7B39FC5Q37982378-4E0AF8BC-BE3E-4623-B879-F78F6AB595A0Q38607819-F584EF28-EED4-441D-9175-628899F46E27Q38790881-8D784736-91F3-40F6-9856-5F653B5213D3Q38805550-D405445A-C901-4A8A-AD93-DEC0BE6DAE8EQ39256792-48BF6F3E-0779-4197-BDC5-3248E61C8858Q40106906-D4F16AFC-DBC1-4C43-AEA6-CBAD20071A99Q40922267-DBDA5E61-90A7-45B3-912D-38AEA8DAC87AQ41740088-C25F5568-669D-4ED3-BD28-20C42A6D644BQ46252300-A997E7B7-15CE-4446-8734-AAD957DEEDECQ47111833-6A679020-4602-4D50-A9B2-98E107813C84Q47304900-697B109B-3233-46F4-A0B3-A61726BF38B0Q47870847-0CBAD826-7987-42CD-AFCA-ECA244F19C7FQ53684476-3D115732-5CE2-4BB0-B8B0-207DEFFB2B78Q54486835-3E13BDB0-C44A-42C8-96FF-15463F15EA20
P2860
Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model t
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Expression of human A53T alpha ...... tion with potential to model t
@ast
Expression of human A53T alpha ...... tion with potential to model t
@en
Expression of human A53T alpha ...... tion with potential to model t
@nl
type
label
Expression of human A53T alpha ...... tion with potential to model t
@ast
Expression of human A53T alpha ...... tion with potential to model t
@en
Expression of human A53T alpha ...... tion with potential to model t
@nl
prefLabel
Expression of human A53T alpha ...... tion with potential to model t
@ast
Expression of human A53T alpha ...... tion with potential to model t
@en
Expression of human A53T alpha ...... tion with potential to model t
@nl
P2093
P2860
P921
P356
P1476
Expression of human A53T alpha ...... tion with potential to model t
@en
P2093
James B Koprich
M Gabriela Reyes
Tom H Johnston
P2860
P2888
P356
10.1186/1750-1326-5-43
P577
2010-10-28T00:00:00Z
P5875
P6179
1011510038